Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/111642
Title: The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study
Author: Gómez Acebo, Inés
Dierssen Sotos, Trinidad
Palazuelos-Calderón, Camilo
Pérez Gómez, Beatriz
Lope, Virginia
Tusquets, Ignasi
Alonso, M. Henar
Moreno Aguado, Víctor
Amiano, Pilar
Molina de la Torre, Antonio José
Barricarte, Aurelio
Tardón, Adonina
Camacho, Antonio
Peiró, Rosana
Marcos Gragera, Rafael
Muñoz, Montse
Michelena-Echeveste, Maria Jesus
Ortega Valin, Luis
Guevara, Marcela
Castaño-Vinyals, Gemma
Aragonés, Nuria
Kogevinas, Manolis
Pollán, Marina
Llorca Díaz, Javier
Keywords: Càncer de mama
Hormones
Hormonoteràpia
Oncologia
Canals de calci
Breast cancer
Hormones
Hormone therapy
Oncology
Calcium channels
Issue Date: 10-Aug-2016
Publisher: Public Library of Science (PLoS)
Abstract: INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. METHODS: In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. RESULTS: The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. CONCLUSIONS: In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0159672
It is part of: PLoS One, 2016, vol. 11, num. 8, p. e0159672
Related resource: https://doi.org/10.1371/journal.pone.0159672
URI: http://hdl.handle.net/2445/111642
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
665137.pdf223.94 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons